- Datum21.04.2026
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
stock3
Equillium Inc. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
6,77 %
Intraday
7,33 %
1 Woche
-11,64 %
1 Monat
32,26 %
Seit Jahresbeginn
368,68 %
1 Jahr
188,73 %
3 Jahre
-69,13 %
5 Jahre
Passender Service zu Equillium Inc.
Webinar zu Equillium Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,270-2,700
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Equillium Inc.
Keine Dividenden verfügbar
Termine von Equillium Inc.
Keine aktuellen Termine
Beschreibung
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
